Pivotal adult trial data support planned BLA submission for Vaxcyte's investigational 31-valent pneumococcal conjugate ...

VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified Co-Primary Immunogenicity Endpoints: In Adults 50 and ...

Tower Transit has acquired PCV driver training business Abacus UK Training of Huyton. It builds on the earlier integration of ...

Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead.

The World Health Organization (WHO) and the United States Department of State both formally requested more information from ...

Vaxcyte's stock has skyrocketed as its invasive pneumococcal disease (IPD) and pneumococcal pneumonia vaccine has met its ...

The VAX-31 pneumococcal conjugate vaccine (PCV) candidate met all prespecified primary endpoints in OPUS-1, the pivotal adult phase 3 trial, according to the vaccine’s manufactu ...

Shares of Vaxcyte, a US clinical-stage vaccine innovation company, rocketed as much as 90% in pre-market activity today ...

Vaxcyte priced US$500M in stock and pre-funded warrants alongside US$500M in 1.5 per cent notes, with an Oct. 9 close ...

Vaxcyte, Inc. announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company?s next-generation 31-valent ...

Detailed price information for Aspen Pharmacre Hl ADR (APNHY) from The Globe and Mail including charting and trades.